BIOMAT Database Logo BIOMAT Database Logo

Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine. 1991

V I Levenson, and T P Egorova, and Z P Belkin, and V G Fedosova, and J L Subbotina, and E Z Rukhadze, and E K Dzhikidze, and Z K Stassilevich
Laboratory of Subcellular Bacterial Structures, Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Moscow, USSR.

A parenteral Shigella ribosomal vaccine (SRV) was investigated in animals for safety, antibody-inducing capacity, and protective activity. Ribosomal preparations from a Shigella sonnei phase I avirulent strain were obtained and shown to possess chemical, sedimentation, and other properties typical of bacterial ribosomes. No endotoxin contamination was revealed by a ketodeoxyoctonate assay, although the presence of some kind of O antigen was evidenced by serological findings and the high activity of SRV in inducing the O-antibody response and immunological memory in animals. SRV was nontoxic in mice, guinea pigs, and monkeys and induced no local reactions when injected subcutaneously in reasonable doses. Significant protection against a local Shigella infection (Sereny test) was seen in guinea pigs injected with SRV (efficiency index, about 60%) and the specificity of the protection was evident from cross-challenge experiments. The protective efficiency of SRV was especially high in rhesus monkeys challenged orally with virulent Shigella cells (89%, as calculated from the summarized data of several experiments in 71 animals). Protection in monkeys was long lasting and could be demonstrated several months after injection of SRV. An inexpensive technique can be used for the production of SRV on a large scale. The high immunogenicity of SRV is discussed in terms of the amplifying effect of the ribosome, which serves as a delivery system for polysaccharide O antigen. Further study of SRV as a candidate vaccine for humans seems justified by the data obtained.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007526 Isoelectric Point The pH in solutions of proteins and related compounds at which the dipolar ions are at a maximum. Isoelectric Points,Point, Isoelectric,Points, Isoelectric
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D008297 Male Males
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D004405 Dysentery, Bacillary DYSENTERY caused by gram-negative rod-shaped enteric bacteria (ENTEROBACTERIACEAE), most often by the genus SHIGELLA. Shigella dysentery, Shigellosis, is classified into subgroups according to syndrome severity and the infectious species. Group A: SHIGELLA DYSENTERIAE (severest); Group B: SHIGELLA FLEXNERI; Group C: SHIGELLA BOYDII; and Group D: SHIGELLA SONNEI (mildest). Shigellosis,Dysentery, Shiga bacillus,Dysentery, Shigella boydii,Dysentery, Shigella dysenteriae,Dysentery, Shigella dysenteriae type 1,Dysentery, Shigella flexneri,Dysentery, Shigella sonnei,Shigella Dysentery,Shigella Infection,Bacillary Dysentery,Dysenteries, Shigella,Dysenteries, Shigella boydii,Dysenteries, Shigella dysenteriae,Dysenteries, Shigella flexneri,Dysenteries, Shigella sonnei,Dysentery, Shigella,Infection, Shigella,Infections, Shigella,Shiga bacillus Dysentery,Shigella Dysenteries,Shigella Infections,Shigella boydii Dysenteries,Shigella boydii Dysentery,Shigella dysenteriae Dysenteries,Shigella dysenteriae Dysentery,Shigella flexneri Dysenteries,Shigella flexneri Dysentery,Shigella sonnei Dysenteries,Shigella sonnei Dysentery
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies

Related Publications

V I Levenson, and T P Egorova, and Z P Belkin, and V G Fedosova, and J L Subbotina, and E Z Rukhadze, and E K Dzhikidze, and Z K Stassilevich
Shigella Sonnei vaccine.
September 1999, Drugs in R&D,
V I Levenson, and T P Egorova, and Z P Belkin, and V G Fedosova, and J L Subbotina, and E Z Rukhadze, and E K Dzhikidze, and Z K Stassilevich
Protective milk O antibodies induced in guinea pigs by parenteral Shigella ribosomal vaccine.
January 1990, International archives of allergy and applied immunology,
V I Levenson, and T P Egorova, and Z P Belkin, and V G Fedosova, and J L Subbotina, and E Z Rukhadze, and E K Dzhikidze, and Z K Stassilevich
[The effect of a ribosomal Shigella sonnei vaccine on cellular immune reactions].
January 1992, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
V I Levenson, and T P Egorova, and Z P Belkin, and V G Fedosova, and J L Subbotina, and E Z Rukhadze, and E K Dzhikidze, and Z K Stassilevich
Shigella sonnei Does Not Use Amoebae as Protective Hosts.
May 2018, Applied and environmental microbiology,
V I Levenson, and T P Egorova, and Z P Belkin, and V G Fedosova, and J L Subbotina, and E Z Rukhadze, and E K Dzhikidze, and Z K Stassilevich
Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease.
August 1990, Vaccine,
V I Levenson, and T P Egorova, and Z P Belkin, and V G Fedosova, and J L Subbotina, and E Z Rukhadze, and E K Dzhikidze, and Z K Stassilevich
[Ribosomal dysentery vaccine. IV. Study of the reactogenicity, antigenic and protective activity of Shigella sonnei ribosomes in monkey experiments].
July 1981, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
V I Levenson, and T P Egorova, and Z P Belkin, and V G Fedosova, and J L Subbotina, and E Z Rukhadze, and E K Dzhikidze, and Z K Stassilevich
Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.
August 2011, Vaccine,
V I Levenson, and T P Egorova, and Z P Belkin, and V G Fedosova, and J L Subbotina, and E Z Rukhadze, and E K Dzhikidze, and Z K Stassilevich
Construction of a stable and non-resistant bivalent vaccine candidate strain against Shigella flexneri 2a and Shigella sonnei.
January 1996, Chinese journal of biotechnology,
V I Levenson, and T P Egorova, and Z P Belkin, and V G Fedosova, and J L Subbotina, and E Z Rukhadze, and E K Dzhikidze, and Z K Stassilevich
Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
June 2007, Vaccine,
V I Levenson, and T P Egorova, and Z P Belkin, and V G Fedosova, and J L Subbotina, and E Z Rukhadze, and E K Dzhikidze, and Z K Stassilevich
[Isolation of endotoxin-free Shigella sonnei enterotoxin from a neurotoxin preparation].
April 1980, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
Copied contents to your clipboard!